Clinical trials
Hematopoietic Stem Cell Transplant clinical trials
Below are recruiting hematopoietic stem cell transplant clinical trials, each written for real people, not researchers. We’re tracking 371 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT05190653Recruiting
Support during stem cell or CAR T cancer treatment
This study tests whether starting palliative and supportive care early (alongside cancer treatment) can improve comfort and support for people having stem cell transplant or CAR T-cell therapy. It may also help family caregivers by offering support during a difficult treatment period.
Calgary, AlbertaAges 18 years+ - NCT06851767Enrolling by invitationPhase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency
This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.
Bethesda, MarylandAges 3–99 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT04774536RecruitingPhase 1/Phase 2
CRISPR gene-edited bone marrow transplant for severe sickle cell
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
Los Angeles, CaliforniaAges 12–35 - NCT05664126RecruitingPhase 2
Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Memphis, TennesseeAges Up to 18 years - NCT04210791Enrolling by invitation
Stem cell transplant using your own cells for AL amyloidosis
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Nanjing, JiangsuAges 18–75 - NCT05477589RecruitingPhase 3
Conditioning plan for kids with AML before stem cell transplant
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
BrusselsAges Up to 18 years - NCT06647979RecruitingPhase 1
Gene editing for severe sickle cell or thalassemia
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Boston, MassachusettsAges 13–40 - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60 - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT05509933RecruitingPhase 3
Budesonide to prevent engraftment syndrome after stem cell transplant
This Phase 3 study tests whether budesonide can prevent “engraftment syndrome” after people receive a hematopoietic (blood-forming) stem cell transplant. If it works, it may reduce complications around the time the new cells start growing and making blood cells.
Detroit, MichiganAges 18–80 - NCT04099082Recruiting
Predicting lung scarring after a specific viral infection
This study looks at how your immune response to a particular virus (PIV) might predict future lung scarring called bronchiolitis obliterans. It may help doctors better identify who is at higher risk after a stem cell transplant.
Paris, Île-de-France RegionAges 18 years+ - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT05773729Recruiting
Gene-modified own stem cell treatment for transfusion-dependent thalassemia
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
ShanghaiAges 3–18 - NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
ShanghaiAges 6–35 - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06548958Recruiting
TBI and chemotherapy before a second stem cell transplant
This trial tests a combination of total body irradiation and two chemotherapy drugs as preparation for a second stem cell transplant in people with blood cancers that relapsed or didn't respond to the first transplant.
Suzhou, JiangsuAges 14–70 - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT04691284Recruiting
Test how the gut microbiome changes during major cancer treatment
This study looks at your gut “microbiome” (the bacteria in your intestines) while you receive high-dose chemotherapy and a stem cell transplant, or CAR-T cell therapy. Researchers hope to understand how these treatments affect the microbiome, which may relate to how well patients do.
Bratislava, SlovakiaAges 18 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70
Hear when a new Hematopoietic Stem Cell Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematopoietic stem cell transplant?
- Yes. Clin2 currently lists 371 recruiting hematopoietic stem cell transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematopoietic stem cell transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematopoietic stem cell transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplant Complications
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplant
- Hematopoietic Cell Transplant
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.